Literature DB >> 10486195

Clenbuterol, a beta(2)-adrenoceptor agonist, improves locomotor and histological outcomes after spinal cord contusion in rats.

R J Zeman1, Y Feng, H Peng, J D Etlinger.   

Abstract

An important goal of rehabilitation following spinal cord injury is recovery of locomotor function and muscular strength. In the present studies, we determined whether the beta(2)-agonist, clenbuterol, can improve recovery of locomotor function following spinal cord injury. A model of spinal cord injury was examined in which four graded levels of contusion injury were produced in rats at the level of T10 with a weight-drop device. Locomotor recovery was determined with the Basso, Beattie, and Bresnahan (BBB) scale, which distinguishes between 22 progressive levels of recovery. As observed previously, recovery during the 6 weeks following injury was inversely related to the severity of injury. However, clenbuterol caused substantial enhancement of recovery of locomotor function at the two most severe levels of injury (BBB scores 10-12 vs 2-4). In addition, the extent of recovery was directly related to sparing of spinal cord tissue at the contusion center in both untreated and clenbuterol-treated spinal cords. Optimization of beta(2)-agonist treatment may lead to a useful therapeutic modality for treatment of spinal cord contusion injury. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486195     DOI: 10.1006/exnr.1999.7146

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  6 in total

1.  Partial functional recovery after complete spinal cord transection by combined chondroitinase and clenbuterol treatment.

Authors:  Fusheng Bai; Hong Peng; Joseph D Etlinger; Richard J Zeman
Journal:  Pflugers Arch       Date:  2010-06-16       Impact factor: 3.657

2.  Pharmacological Stimulation of Mitochondrial Biogenesis Using the Food and Drug Administration-Approved β2-Adrenoreceptor Agonist Formoterol for the Treatment of Spinal Cord Injury.

Authors:  Natalie E Scholpa; Hannah Williams; Wenxue Wang; Daniel Corum; Aarti Narang; Stephen Tomlinson; Patrick G Sullivan; Alexander G Rabchevsky; Rick G Schnellmann
Journal:  J Neurotrauma       Date:  2018-11-16       Impact factor: 5.269

3.  The effect of adrenergic β(2) receptor agonist on paraplegia following clamping of abdominal aorta.

Authors:  Bok Y Lee; Noori Al-Waili; Glenn Butler
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

4.  Dose-effects of aorta-infused clenbuterol on spinal cord ischemia-reperfusion injury in rabbits.

Authors:  Binbin Chen; Yi Zhang; Lianhua Chen; Shiwei Huang; Shitong Li; Junyan Yao
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

5.  Stem cell therapy and curcumin synergistically enhance recovery from spinal cord injury.

Authors:  D Ryan Ormond; Craig Shannon; Julius Oppenheim; Richard Zeman; Kaushik Das; Raj Murali; Meena Jhanwar-Uniyal
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

6.  The Integrated Transcriptome Bioinformatics Analysis Identifies Key Genes and Cellular Components for Spinal Cord Injury-Related Neuropathic Pain.

Authors:  Runzhi Huang; Tong Meng; Rui Zhu; Lijuan Zhao; Dianwen Song; Huabin Yin; Zongqiang Huang; Liming Cheng; Jie Zhang
Journal:  Front Bioeng Biotechnol       Date:  2020-02-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.